Haemonetics (HAE) Income from Continuing Operations (2009 - 2026)

Haemonetics' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 20147000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 134.75% year-over-year to 20147000.0 in Q1 2026; TTM through Mar 2026 was 97347000.0, a 41.95% decrease from a year earlier, with the FY2026 full-year figure at 97308000.0, down 41.97% from the prior year.
• Income from Continuing Operations retreated to 20147000.0 in Q1 2026 per HAE's latest filing, from 44740000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 57981000.0 in Q1 2025 and bottomed at 20147000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 33051500.0 (2022), against an average of 29502888.89.
• Across the five-year window, Income from Continuing Operations soared 546.27% in 2022 and sank 134.75% in 2026, its largest moves.
• Year by year, Income from Continuing Operations stood at 32944000.0 in 2022, then retreated by 5.17% to 31241000.0 in 2023, then gained by 20.09% to 37517000.0 in 2024, then gained by 19.25% to 44740000.0 in 2025, then plunged by 145.03% to 20147000.0 in 2026.
• Per Business Quant, the three latest HAE Income from Continuing Operations figures stand at 20147000.0 (Q1 2026), 44740000.0 (Q4 2025), and 38685000.0 (Q3 2025).